912-352-7546

FDA Removed the Suicidal Thoughts Warning From GLP-1 Labels: What the Evidence Actually Showed

By Dr. Don Gates, MD, Founder of Scale Solutions

Group exercise class stretching together under live oaks in Forsyth Park, Savannah, for an article on whether the suicide warning is still on Wegovy

No — the suicidal behavior and ideation warning has been removed from Wegovy. On January 13, 2026, the FDA announced it had asked the manufacturers of Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide) to remove that Warning and Precaution from the prescribing information, after a review that found no increased risk. FDA updated the communication on April 3, 2026. The removal is now reflected in the labels themselves: the Recent Major Changes section of the Wegovy label records the removal as 01/2026, and the Zepbound label records it as 02/2026. We were not able to independently confirm the corresponding revision in the Saxenda label.

That is reassuring news, and it is worth understanding why: this is drug safety monitoring working as intended. A signal appeared, FDA investigated it for more than two years, gathered far better data than the original reports, and corrected the record in the direction the evidence pointed.

It is also worth being precise about what the change means. A label change is a statement about populations, not a promise about individuals. If your mood has changed since you started a GLP-1, that is still worth telling your physician about.

FDA labeling status verified against fda.gov as of August 19, 2026.

Key Takeaways

  • FDA requested removal of the suicidal behavior and ideation warning on January 13, 2026 (communication updated April 3, 2026) for Saxenda, Wegovy, and Zepbound. The removal is confirmed implemented in the Wegovy (01/2026) and Zepbound (02/2026) labels; the Saxenda label revision could not be independently confirmed.
  • The decision rested on a meta-analysis of 91 placebo-controlled trials including 107,910 patients and a retrospective cohort of about 2.24 million people. Neither found an increased risk of suicidal ideation or behavior — or of depression, anxiety, irritability, or psychosis.
  • “No increased risk” means no measurable population-level increase. It does not mean no individual ever experiences a mood change on these medications.
  • FDA still tells patients to report new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior to their clinician. That advice did not change.
  • If you are having thoughts of harming yourself, get help now — call or text 988 (Suicide and Crisis Lifeline) or go to an emergency department.

Is the suicide warning still on the Wegovy label?

No. FDA requested its removal from Wegovy, Saxenda, and Zepbound, and the Wegovy and Zepbound labels now show the warning as removed (01/2026 and 02/2026 respectively). The agency stated its conclusion plainly: “FDA’s Evaluation Did Not Identify an Increased Risk of Suicidal Ideation or Behavior.”

Three clarifications:

  • This was a Warning and Precaution, not a boxed warning. The boxed warning about thyroid C-cell tumors in rodents — and the contraindication for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 — is separate and remains in place.
  • Label updates take time to appear everywhere. FDA requests labeling changes; manufacturers then revise the prescribing information, and printed materials, pharmacy handouts, and third-party sites update on their own schedules. You may still encounter the old language.
  • The removal covers the three obesity products FDA named. Each medication carries its own labeling; do not assume this describes every warning on every GLP-1 product.

Why was the suicide warning on Wegovy in the first place?

This is the part most coverage skipped, and it is what makes the 2026 news mean something.

In July 2023, FDA began investigating a potential risk of suicidal ideation and behavior with GLP-1 receptor agonists after receiving postmarketing adverse event reports — voluntary accounts submitted after a drug reaches the market. These reports are the smoke detector of drug safety: sensitive, valuable, and by design not proof of anything. A report tells you someone taking a drug experienced an event. It cannot tell you whether the drug caused it, or whether the event happens more often than it would in similar people not taking it.

FDA published a preliminary evaluation on January 11, 2024. Its assessment was careful and, in retrospect, exactly right: the reports “did not demonstrate a clear relationship with the use of GLP-1 RAs,” because “the information provided was often limited and because these events can be influenced by other potential factors.” But FDA did not close the file. Its conclusion was: “we cannot definitively rule out that a small risk may exist; therefore, FDA is continuing to look into this issue.”

That is what a regulator saying “I don’t know yet” looks like. The warning stayed on the label while better evidence was assembled. Two years later the evidence arrived — and it pointed the other way. That sequence is also a useful template for reading the next drug safety headline: an early signal is a question, not an answer.

What evidence did the FDA actually review?

FDA used two different study designs — the methodologically strong move, because each covers the other’s weaknesses.

 Meta-analysis of randomized trialsRetrospective cohort study
Size91 placebo-controlled trials, 107,910 patients (roughly 60,000 on a GLP-1, roughly 48,000 on placebo)2,243,138 adults
ComparisonGLP-1 vs. placeboGLP-1 users vs. users of SGLT2 inhibitors, a different medication class
Data sourceClinical trial dataFDA’s Sentinel System, using administrative health claims
Time periodTrial durations varyOctober 1, 2015 – September 20, 2023
Main strengthRandomization balances known and unknown differences between groupsReal-world patients, enormous numbers, long follow-up
Main limitationTrial participants are screened and may not mirror everyone in practiceObservational — it can measure association, not prove causation
ResultNo increased risk of suicidal ideation or behavior, or of other relevant psychiatric adverse eventsNo increased risk of intentional self-harm

Two design details deserve credit. The trials were randomized, which is the only reliable way to balance the things researchers cannot measure — important here, because obesity and depression frequently occur together and a simple before-and-after comparison would be hopelessly confounded. And the cohort study used an active comparator: rather than comparing GLP-1 users to the general population, FDA compared them to people starting SGLT2 inhibitors, another class prescribed for broadly similar cardiometabolic reasons. That substantially reduces “confounding by indication” — the tendency for the reason a drug was prescribed to masquerade as an effect of the drug.

FDA also looked beyond suicide specifically, finding no increased risk of anxiety, depression, irritability, or psychosis. That breadth matters: if these medications were quietly destabilizing mood, you would expect signals in the surrounding psychiatric outcomes, not only in the rarest and most severe one.

What “no increased risk” does and does not mean

This distinction is where careful reading pays off.

What it means: Across more than 100,000 randomized patients and more than 2 million real-world patients, researchers could not detect an increase in these outcomes among GLP-1 users compared with the comparison groups. At those sample sizes, if a meaningful population-level increase existed, these analyses were well positioned to find it. That is a strong and genuinely reassuring result.

What it does not mean:

  • It is not proof of zero risk. Statistical studies estimate a range of plausible effects. A study this large can confidently exclude a moderate or large effect; no study can prove an effect is exactly zero. That is a limitation of statistics itself, not a weakness peculiar to this review.
  • It is not a statement about you. Population averages do not describe individual experiences. Some people do notice mood changes after starting a GLP-1, and a null result at the population level does not invalidate that.
  • It does not mean nothing else could be going on. Rapid weight loss is a substantial life change: eating patterns, sleep, energy, body image, and sometimes relationships all shift, and some people lose a coping mechanism they had been relying on. None of that requires a direct drug effect to be real and worth addressing.
  • It does not remove pre-existing depression from the picture. Depression is common, including among people seeking obesity treatment. Someone can have a depressive episode while taking a GLP-1 for reasons unrelated to the medication — and still need treatment for it.

The honest summary: the evidence does not support the idea that these medications cause suicidal thoughts. The evidence has never said that people taking them are immune to depression.

Mental health is part of weight management, whatever the label says

Obesity and depression co-occur far more often than chance would predict, and the relationship runs in both directions — depression can contribute to weight gain, and living with obesity, including the stigma attached to it, can contribute to depression. Several medications used for depression also affect weight. That is ordinary clinical reality, and it does not go away because a warning came off a label.

A good medical weight-management plan therefore accounts for mental health as routine, not as an afterthought triggered by a warning:

  • Baseline matters. A history of depression, anxiety, an eating disorder, or prior suicidal ideation changes how a clinician monitors and what they watch for.
  • Medication lists matter. Many patients starting a GLP-1 already take an antidepressant or other psychiatric medication. That deserves review by someone who can see the whole list.
  • Follow-up matters. The 2026 Standards of Care for obesity pharmacotherapy call for monthly follow-up in the first three months, then every three months for the first year, and every three to six months long term. Repeated visits with the same clinician are precisely how a subtle mood change gets noticed — patients often do not report it spontaneously, but someone who saw you two months ago may recognize the difference.
  • Referral matters. Weight-management clinicians are not a substitute for mental health care. FDA’s guidance to health care professionals says this directly: refer patients who disclose suicidal ideation or behavior to a mental health professional for evaluation.

Related: how we monitor patients on GLP-1 therapy.

When to Talk to Your Doctor

Seek help immediately — do not wait for an appointment — if you are having thoughts of harming or killing yourself, or if you have a plan or intent to act. In the United States you can call or text 988 to reach the Suicide and Crisis Lifeline, 24 hours a day. You can also go to your nearest emergency department or call 911. FDA’s own patient guidance points to 988. This is true regardless of what medication you are taking and regardless of what any label says. Reaching out is the right move, and it is not an overreaction.

Contact your physician promptly — within days, not months — if you notice:

  • New or worsening depressed mood, hopelessness, or loss of interest in things you normally enjoy
  • Unusual changes in mood, personality, or behavior that people close to you have noticed
  • New or worsening anxiety, agitation, irritability, or restlessness
  • A significant change in sleep, particularly new insomnia or early-morning waking
  • Increased alcohol use or other changes in coping behavior
  • Any concern about whether a medication you are taking is affecting how you feel

Routine follow-up is the right setting for:

  • A personal or family history of depression, anxiety, or an eating disorder that you want factored into your treatment plan
  • Questions about how a GLP-1 fits alongside an antidepressant or other psychiatric medication
  • Wanting to understand which warnings currently apply to your specific prescription
  • General questions about what this label change means for you

One thing not to do: do not stop, start, or change the dose of a prescribed medication on your own based on a news headline — in either direction. FDA’s guidance to patients on this point is direct: continue taking your medication as prescribed and discuss any concerns with your health care professional. That decision belongs in a conversation with the clinician who knows your history.

Scale Solutions & Coastal Georgia

A warning label can be added or removed with a regulatory letter. Recognizing that a patient does not seem like themselves takes a clinician who has seen that patient before.

That is the practical argument for a local, physician-led relationship rather than a prescription-only arrangement. Mood changes rarely announce themselves. They show up as a shorter answer than usual, a missed appointment, a slip in something the patient was doing well two months ago. Continuity is what makes that visible — the same practice, the same records, follow-up at a real cadence, and the ability to coordinate with a patient’s primary care physician or point them toward behavioral health resources here in the community.

That is how Scale Solutions approaches care for patients in Savannah, Pooler, Richmond Hill, Hinesville, and across Chatham and Bryan counties. Weight, labs, side effects, and how you are actually doing are all part of the same visit.

If you are taking a GLP-1 and you have noticed a change in your mood, or you have a history of depression or anxiety and want that considered carefully before starting treatment, you are welcome to reach out to us. It is a normal thing to raise, we would rather hear about it early, and no one at this practice will treat it as an inconvenient question.

See also: what FDA safety data actually shows about GLP-1 medications.

See also: the side effects patients actually report.

See also: our GLP-1 weight-loss program.

See also: our editorial and medical review policy.

Frequently Asked Questions: Is the Suicide Warning Still on Wegovy?

Is the suicide warning still on Wegovy? No. On January 13, 2026, FDA requested that the suicidal behavior and ideation Warning and Precaution be removed from Wegovy, Saxenda, and Zepbound after finding no increased risk. Older printed materials and third-party websites may still show the previous language.

Does this mean Wegovy or Zepbound cannot affect my mood at all? No — that is an important distinction. FDA’s finding is that these medications do not increase the risk of suicidal ideation, self-harm, depression, anxiety, irritability, or psychosis at a population level. It is not a claim that no individual ever experiences a mood change. If your mood has changed, tell your physician.

Why did the FDA investigate this in the first place? FDA began looking into it in July 2023 after receiving postmarketing adverse event reports. Its January 2024 preliminary review found those reports did not demonstrate a clear relationship with GLP-1 use, but concluded that “we cannot definitively rule out that a small risk may exist.” The warning stayed in place while the agency kept investigating.

How strong is the evidence behind the removal? Substantial. FDA reviewed a meta-analysis of 91 placebo-controlled trials involving 107,910 patients, plus a retrospective cohort of about 2.24 million people comparing GLP-1 users with SGLT2 inhibitor users, drawn from FDA’s Sentinel System and covering October 2015 through September 2023. Neither found an increased risk. Using both a randomized and an observational design is a deliberate strength — each covers the other’s weaknesses.

I have a history of depression. Can I still take a GLP-1 medication? That is a decision for you and a clinician who knows your full history and medication list; an article cannot answer it. What the current evidence supports is that a history of depression is not by itself an automatic barrier — and that it is information your clinician should have before treatment starts and should keep monitoring afterward.

Should I stop my GLP-1 because I have been feeling low? Do not make that change on your own. Call your prescribing clinician and describe what you are experiencing. There are several possible explanations, including ones unrelated to the medication, and sorting them out is a clinical conversation. If you are having thoughts of harming yourself, seek help immediately by calling or texting 988 or going to an emergency department.

What warnings are still on these medications? Several. GLP-1 medications approved for weight management carry a boxed warning about thyroid C-cell tumors seen in rodents, with a contraindication for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Labeled warnings across the class also include pancreatitis, gallbladder disease, hypoglycemia (particularly alongside insulin or sulfonylureas), acute kidney injury from dehydration, diabetic retinopathy complications, risk of pulmonary aspiration during general anesthesia or deep sedation, hypersensitivity reactions, and contraindication in pregnancy. Removing one warning did not empty the label.

Conclusion: The Suicide Warning Is No Longer on Wegovy, but Mental Health Still Matters

FDA asked for the suicidal behavior and ideation warning to be removed from Saxenda, Wegovy, and Zepbound because two large analyses — covering more than 100,000 randomized patients and more than 2 million real-world patients — found no increased risk of suicidal thoughts, self-harm, or related psychiatric outcomes. The warning was there because a signal deserved investigation; it came off because the investigation produced an answer. That sequence should increase your confidence in the process, not only in the result.

What has not changed is the value of telling someone when you are not feeling right. Depression is common, weight loss is a significant life change, and a regulatory finding about averages is not a verdict on your experience.

If you are in Savannah or anywhere in Coastal Georgia and you have questions about GLP-1 treatment — including how a history of depression or anxiety fits into your plan, or a change in mood you have noticed since starting — Scale Solutions is here and glad to talk it through. You can contact our office to arrange a visit with a physician who will look at your whole history, not just the number on the scale.

And if you are in crisis right now, please call or text 988 before you finish reading this page.

MEDICAL SOURCES & FURTHER READING

  1. U.S. Food and Drug Administration. FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications. Drug Safety Communication issued January 13, 2026; content current as of April 3, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp (Source for: the removal request; the drugs affected; the 91-trial / 107,910-patient meta-analysis; the 2,243,138-patient Sentinel cohort vs. SGLT2 inhibitors, October 2015–September 2023; the finding of no increased risk of suicidal ideation or behavior, anxiety, depression, irritability, or psychosis; guidance to patients and health care professionals; the reference to 988.)

  2. U.S. Food and Drug Administration. Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. January 11, 2024. https://www.fda.gov/drugs/drug-safety-communications/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type (Source for: the July 2023 start of the investigation; the limitations of postmarketing reports; the verbatim conclusion “we cannot definitively rule out that a small risk may exist.”)

  3. U.S. Food and Drug Administration — Drugs@FDA. Current prescribing information for Wegovy, Zepbound, and Saxenda. https://www.accessdata.fda.gov/scripts/cder/daf/ (Source for: current boxed warning and Warnings and Precautions content. Labels are revised periodically — check the revision date on the label itself.)

  4. FDA Sentinel Initiative. https://www.sentinelinitiative.org/ (Background on the national medical product safety surveillance system used for the retrospective cohort analysis.)

  5. Gudzune KA, et al.; American Diabetes Association Professional Practice Committee for Obesity. Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity. Published January 13, 2026. DOI 10.2337/doci25-0008. Free full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC12815056/ (Source for: recommended follow-up cadence during obesity pharmacotherapy — monthly for the first three months, every three months for the first year, then every three to six months long term.)

  6. 988 Suicide and Crisis Lifeline (Substance Abuse and Mental Health Services Administration). https://988lifeline.org/ (Free, confidential, 24/7 support in the United States by call or text.)